BeOne Medicines Presents Phase 3 Data for CLL in Elderly Patients
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 11 2026
0mins
BeOne Medicines announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, CLL/SLL, aged 80 and older, showing sustained benefit with Brukinsa after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. Brukinsa is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial. These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association, EHA, Congress in Stockholm, Sweden. Key highlights: Sequoia subgroup analysis showed that age did not limit benefit in patients with CLL treated with Brukinsa; 78-month Sequoia data reinforce Brukinsa as the "foundational BTK inhibitor" in CLL; Real-world efficacy and safety data consistently underscore "foundational Brukinsa as the best-in-class BTKi" for TN CLL
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ONC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ONC
Wall Street analysts forecast ONC stock price to rise
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 309.460
Low
385.00
Averages
403.76
High
424.00
Current: 309.460
Low
385.00
Averages
403.76
High
424.00
About ONC
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SPDR S&P 500 ETF Trust Sees Marginal Increase
- Market Performance: The SPDR S&P 500 ETF Trust (SPY) experienced a marginal increase, reflecting a cautiously optimistic sentiment among investors despite ongoing market volatility.
- Investor Sentiment: The slight rise in this ETF indicates that investors maintain confidence in the performance of large corporations in the current economic climate, potentially attracting more capital inflows.
- Market Trends: As expectations for economic recovery strengthen, SPY's performance may influence the trajectory of other related assets, further promoting overall market stability.
- Strategic Implications: The increase in SPY could prompt investors to reassess their portfolios, especially in the face of potential market uncertainties, possibly leading to a shift of funds towards safer assets.
See More
BRUKINSA Plus Rituximab Significantly Improves Outcomes in MCL Patients
- Clinical Trial Success: The MANGROVE study demonstrated that BRUKINSA combined with rituximab reduced the risk of progression or death by 43% compared to the traditional bendamustine plus rituximab regimen (HR=0.57; p<0.0001), marking the first chemotherapy-free standard in frontline MCL treatment and potentially redefining global treatment paradigms.
- Reduced Patient Burden: This chemotherapy-free approach spares patients from approximately two years of frequent infusions, significantly alleviating the treatment burden for older patients and enhancing their quality of life, addressing the urgent need for new therapeutic options.
- Global Regulatory Plans: BeOne Medicines plans to submit applications to global regulatory authorities in the second half of 2026, further advancing BRUKINSA's market access and expected to provide more effective treatment options for MCL patients, thereby enhancing the company's competitiveness in oncology.
- Future Outlook: Full results from the MANGROVE study will be presented at an upcoming medical meeting, which is anticipated to provide additional data support for BRUKINSA's clinical application, solidifying its foundational role in the treatment of B-cell malignancies.
See More
Kymera Therapeutics Appoints New Chairman of the Board
- Board Leadership Change: Kymera Therapeutics announced the appointment of Felix J. Baker as the new Chairman of the Board, succeeding Bruce Booth, who has held the position since 2016 and will remain on the Board as an Independent Director, ensuring continuity and stability in corporate governance.
- Management Background: Baker has served as the company's Lead Independent Director since 2024 and is a Managing Member of Baker Brothers Investment, co-founded in 2000, which brings extensive experience in biopharmaceutical investments, likely providing stronger strategic guidance for Kymera.
- Stock Performance: Kymera's stock has traded between $36.65 and $105 over the past year, closing at $99.87, up 1.65% from the previous day, indicating market confidence in the company's future prospects.
- After-Hours Trading Dynamics: In after-hours trading, Kymera's shares rose 0.33% to $100.20, reflecting investor optimism regarding the new Chairman's appointment, which may further drive stable growth in the company's stock price.
See More
BeOne's Drug Shows Durable Efficacy in Chronic Lymphocytic Leukemia
- Significant Efficacy: Tacabrutideg demonstrated an overall response rate of 85.1% in heavily pretreated relapsed/refractory chronic lymphocytic leukemia (CLL) patients, with early activity also observed in BTK inhibitor-naïve patients, indicating its potential for earlier lines of treatment.
- Good Safety Profile: In a study of 67 patients, tacabrutideg was generally well tolerated with no treatment-related deaths and no new toxicities identified, leading to rapid and sustained improvements in cytopenia, significantly enhancing patients' quality of life.
- Combination Therapy Potential: The combination of BRUKINSA and sonrotoclax showed deep and durable responses in both treatment-naïve and relapsed/refractory settings, particularly in treatment-naïve CLL where a 100% overall response rate and 59.5% complete response rate were achieved, highlighting its potential as a foundation for time-limited therapy.
- Clinical Data Update: Updated data presented at EHA 2026 indicated a 24-month progression-free survival rate of 53.8% for heavily pretreated patients receiving tacabrutideg, providing critical evidence for future clinical applications and potentially transforming the treatment landscape for B-cell malignancies.
See More
BeOne Medicines Stock Shows Oversold Signal
- Oversold Indicator: BeOne Medicines Ltd (Ticker: ONC) hit an RSI of 28.9 during Thursday's trading, indicating an oversold condition with a low price of $253.9475, suggesting that recent heavy selling may be exhausting.
- Market Comparison: Compared to the S&P 500 ETF (SPY) with an RSI of 51.5, ONC's oversold status could attract bullish investors looking for buying opportunities, reflecting a divergence in market sentiment.
- Price Fluctuation: ONC's 52-week low is $239.25 and high is $385.22, with the latest trade at $260.31, indicating potential for price rebound within its trading range.
- Investor Focus: Investors may pay attention to ONC's oversold signal to identify potential buying opportunities, aiming to capitalize on gains when the market rebounds.
See More
BRUKINSA Shows Long-Term Efficacy in Patients Over 80
- Sustained Efficacy: Nearly two-thirds of patients aged 80 and older treated with BRUKINSA remained progression-free after nearly 6.5 years, demonstrating the drug's effectiveness and tolerability in high-risk groups, reinforcing its role as the foundational BTK inhibitor.
- Clinical Data Highlights: The SEQUOIA subgroup analysis revealed a median age of 81 years with a 100% overall response rate and a 72-month progression-free survival rate of 63.8%, indicating BRUKINSA's therapeutic potential in elderly patients, particularly those with high-risk features.
- Safety Analysis: BRUKINSA exhibited consistent safety profiles in long-term follow-ups, particularly in older patients, with low rates of atrial fibrillation enhancing confidence in its use as a first-line treatment, supporting clinical decision-making.
- Patient Decision Factors: Recent studies indicate that safety, disease severity, and efficacy are the primary considerations for patients choosing first-line CLL treatments, while treatment duration is less influential, highlighting the importance of aligning treatment discussions with patient priorities.
See More
SPDR S&P 500 ETF Trust Sees Marginal Increase
- Market Performance: The SPDR S&P 500 ETF Trust (SPY) experienced a marginal increase, reflecting a cautiously optimistic sentiment among investors despite ongoing market volatility.
- Investor Sentiment: The slight rise in this ETF indicates that investors maintain confidence in the performance of large corporations in the current economic climate, potentially attracting more capital inflows.
- Market Trends: As expectations for economic recovery strengthen, SPY's performance may influence the trajectory of other related assets, further promoting overall market stability.
- Strategic Implications: The increase in SPY could prompt investors to reassess their portfolios, especially in the face of potential market uncertainties, possibly leading to a shift of funds towards safer assets.
See More
BRUKINSA Plus Rituximab Significantly Improves Outcomes in MCL Patients
- Clinical Trial Success: The MANGROVE study demonstrated that BRUKINSA combined with rituximab reduced the risk of progression or death by 43% compared to the traditional bendamustine plus rituximab regimen (HR=0.57; p<0.0001), marking the first chemotherapy-free standard in frontline MCL treatment and potentially redefining global treatment paradigms.
- Reduced Patient Burden: This chemotherapy-free approach spares patients from approximately two years of frequent infusions, significantly alleviating the treatment burden for older patients and enhancing their quality of life, addressing the urgent need for new therapeutic options.
- Global Regulatory Plans: BeOne Medicines plans to submit applications to global regulatory authorities in the second half of 2026, further advancing BRUKINSA's market access and expected to provide more effective treatment options for MCL patients, thereby enhancing the company's competitiveness in oncology.
- Future Outlook: Full results from the MANGROVE study will be presented at an upcoming medical meeting, which is anticipated to provide additional data support for BRUKINSA's clinical application, solidifying its foundational role in the treatment of B-cell malignancies.
See More
Kymera Therapeutics Appoints New Chairman of the Board
- Board Leadership Change: Kymera Therapeutics announced the appointment of Felix J. Baker as the new Chairman of the Board, succeeding Bruce Booth, who has held the position since 2016 and will remain on the Board as an Independent Director, ensuring continuity and stability in corporate governance.
- Management Background: Baker has served as the company's Lead Independent Director since 2024 and is a Managing Member of Baker Brothers Investment, co-founded in 2000, which brings extensive experience in biopharmaceutical investments, likely providing stronger strategic guidance for Kymera.
- Stock Performance: Kymera's stock has traded between $36.65 and $105 over the past year, closing at $99.87, up 1.65% from the previous day, indicating market confidence in the company's future prospects.
- After-Hours Trading Dynamics: In after-hours trading, Kymera's shares rose 0.33% to $100.20, reflecting investor optimism regarding the new Chairman's appointment, which may further drive stable growth in the company's stock price.
See More
BeOne's Drug Shows Durable Efficacy in Chronic Lymphocytic Leukemia
- Significant Efficacy: Tacabrutideg demonstrated an overall response rate of 85.1% in heavily pretreated relapsed/refractory chronic lymphocytic leukemia (CLL) patients, with early activity also observed in BTK inhibitor-naïve patients, indicating its potential for earlier lines of treatment.
- Good Safety Profile: In a study of 67 patients, tacabrutideg was generally well tolerated with no treatment-related deaths and no new toxicities identified, leading to rapid and sustained improvements in cytopenia, significantly enhancing patients' quality of life.
- Combination Therapy Potential: The combination of BRUKINSA and sonrotoclax showed deep and durable responses in both treatment-naïve and relapsed/refractory settings, particularly in treatment-naïve CLL where a 100% overall response rate and 59.5% complete response rate were achieved, highlighting its potential as a foundation for time-limited therapy.
- Clinical Data Update: Updated data presented at EHA 2026 indicated a 24-month progression-free survival rate of 53.8% for heavily pretreated patients receiving tacabrutideg, providing critical evidence for future clinical applications and potentially transforming the treatment landscape for B-cell malignancies.
See More
BeOne Medicines Stock Shows Oversold Signal
- Oversold Indicator: BeOne Medicines Ltd (Ticker: ONC) hit an RSI of 28.9 during Thursday's trading, indicating an oversold condition with a low price of $253.9475, suggesting that recent heavy selling may be exhausting.
- Market Comparison: Compared to the S&P 500 ETF (SPY) with an RSI of 51.5, ONC's oversold status could attract bullish investors looking for buying opportunities, reflecting a divergence in market sentiment.
- Price Fluctuation: ONC's 52-week low is $239.25 and high is $385.22, with the latest trade at $260.31, indicating potential for price rebound within its trading range.
- Investor Focus: Investors may pay attention to ONC's oversold signal to identify potential buying opportunities, aiming to capitalize on gains when the market rebounds.
See More
BRUKINSA Shows Long-Term Efficacy in Patients Over 80
- Sustained Efficacy: Nearly two-thirds of patients aged 80 and older treated with BRUKINSA remained progression-free after nearly 6.5 years, demonstrating the drug's effectiveness and tolerability in high-risk groups, reinforcing its role as the foundational BTK inhibitor.
- Clinical Data Highlights: The SEQUOIA subgroup analysis revealed a median age of 81 years with a 100% overall response rate and a 72-month progression-free survival rate of 63.8%, indicating BRUKINSA's therapeutic potential in elderly patients, particularly those with high-risk features.
- Safety Analysis: BRUKINSA exhibited consistent safety profiles in long-term follow-ups, particularly in older patients, with low rates of atrial fibrillation enhancing confidence in its use as a first-line treatment, supporting clinical decision-making.
- Patient Decision Factors: Recent studies indicate that safety, disease severity, and efficacy are the primary considerations for patients choosing first-line CLL treatments, while treatment duration is less influential, highlighting the importance of aligning treatment discussions with patient priorities.
See More
